Physician profile
Boris Tsukerman
NPI 1942463849
$7,631.64
in general payments reported to CMS, 2019-2025
31 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $1,045 · 2021: $1,536 · 2022: $1,143 · 2023: $635 · 2024: $1,001 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,726.68 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,534.34 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $928.11 | 2019-2023 | |
| Amgen INC. | $524.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $468.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $393.33 | 2021-2025 | |
| Lilly USA, LLC | $295.38 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $263.37 | 2020-2023 | Eliquis |
| Glaxosmithkline, LLC. | $259.28 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Nestle Healthcare Nutrition INC. | $153.10 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $149.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.19 | 2019 | |
| Ardelyx, INC. | $89.52 | 2025 | Ibsrela |
| Genentech USA, INC. | $87.78 | 2019-2020 | |
| Sk Life Science, INC. | $72.24 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $68.72 | 2023-2024 | Accrufer |
| Vistapharm, INC. | $64.12 | 2021 | |
| Pfizer INC. | $64.09 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $44.72 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $44.30 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $38.73 | 2022-2023 | Saxenda, Wegovy |
| Arbor Pharmaceuticals, INC. | $38.08 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $35.50 | 2025 | Amvuttra |
| Exact Sciences Corporation | $25.00 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $23.75 | 2019 | |
| Ironwood Pharmaceuticals, INC | $22.00 | 2020 | |
| Esperion Therapeutics, INC. | $20.83 | 2024 | Nexletol |
| Glycomark, INC. | $20.61 | 2019 | |
| Astellas Pharma US INC | $19.00 | 2023 | Veozah |
| Sanofi Pasteur INC. | $16.72 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Tsukerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.